Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles
| Autor: | Michael Lishner, Liat Drucker, Metsada Pasmanik-Chor, Shelly Tartakover Matalon, Oshrat Attar-Schneider, Osnat Jarchowsky-Dolberg, Mahmoud Dabbah |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male Proteomics Cancer Research Carcinogenesis Primary Cell Culture Cell Separation Integrin alpha4beta1 03 medical and health sciences 0302 clinical medicine Bone Marrow Cell Movement Cell-Derived Microparticles Cell Line Tumor Tumor Microenvironment Humans Aged Cell Proliferation Neoplasm Staging Aged 80 and over Natalizumab Mesenchymal Stem Cells General Medicine Middle Aged Flow Cytometry 030104 developmental biology 030220 oncology & carcinogenesis Female Multiple Myeloma Oligopeptides |
| Zdroj: | Carcinogenesis. 41(1) |
| ISSN: | 1460-2180 |
| Popis: | Multiple myeloma (MM) cells accumulate in the bone marrow (BM) where their interactions impede disease therapy. We have shown that microvesicles (MVs) derived from BM mesenchymal stem cells (MSCs) of MM patients promote the malignant traits via modulation of translation initiation (TI), whereas MVs from normal donors (ND) do not. Here, we observed that this phenomenon is contingent on a MVs’ protein constituent, and determined correlations between the MVs from the tumor microenvironment, for example, MM BM-MSCs and patients’ clinical characteristics. BM-MSCs’ MVs (ND/MM) proteomes were assayed (mass spectrometry) and compared. Elevated integrin CD49d (X80) and CD29 (X2) was determined in MM-MSCs’ MVs and correlated with patients’ staging and treatment response (free light chain, BM plasma cells count, stage, response to treatment). BM-MSCs’ MVs uptake into MM cell lines was assayed (flow cytometry) with/without integrin inhibitors (RGD, natalizumab, and anti-CD29 monoclonal antibody) and recipient cells were analyzed for cell count, migration, MAPKs, TI, and drug response (doxorubicin, Velcade). Their inhibition, particularly together, attenuated the uptake of MM-MSCs MVs (but not ND-MSCs MVs) into MM cells and reduced MM cells’ signaling, phenotype, and increased drug response. This study exposed a critical novel role for CD49d/CD29 on MM-MSCs MVs and presented a discriminate method to inhibit cancer promoting action of MM-MSCs MVs while retaining the anticancer function of ND-MSCs-MVs. Moreover, these findings demonstrate yet again the intricacy of the microenvironment involvement in the malignant process and highlight new therapeutic avenues to be explored. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|